BioCentury | Jul 9, 2019
Financial News

BioNTech broadens investor base with $325M B round

...generation unit of MAB Discovery GmbH in January and its purchase of antibody assets from MabVax Therapeutics Holdings Inc....
BioCentury | Jun 28, 2019
Preclinical News

June 28 Preclinical Quick Takes: BioNTech targets pancreatitis; plus new targets for HIV and more

...CSHL filed a patent application on using anti-CA19.9 mAbs to treat and prevent pancreatitis, which MabVax Therapeutics Holdings Inc....
BioCentury | May 8, 2019
Company News

May 8 Company Quick Takes: Takeda selling Shire eye drug to Novartis in $3.4B deal; plus BioNTech, Third Rock’s Thrive and more

...Diego through its acquisition of antibody assets, including MVT-5873, and infrastructure and lab equipment from MabVax Therapeutics Holdings Inc....
...Chris Lieu Xiidra, lifitegrast (SAR 1118, SHP606) Amgen Inc. BioNTech AG Chiesi Farmaceutici S.p.A. Jiangsu Hansoh Pharmaceutical Co. Ltd. Johnson & Johnson MabVax Therapeutics Holdings Inc. Novartis...
BioCentury | Sep 7, 2018
Financial News

Opko's Frost among those charged in ‘pump-and-dump’ schemes

...said are led by Barry Konig. Two of the companies -- Biozone Pharmaceuticals Inc. and MabVax Therapeutics Holdings Inc....
...New York. Biozone Pharmaceuticals Inc. merged with Cocrystal Pharma Inc. (OTCQB:COCP) in 2014. Allison Johnson Biozone Pharmaceuticals Inc. MabVax Therapeutics Holdings Inc. Opko...
BioCentury | Mar 9, 2018
Clinical News

MabVax reports Phase I data for cancer candidate MVT-1075

...is a human IgG1 mAb targeting an epitope on CA19.9 coupled to the radioisotope lutetium-177. MabVax Therapeutics Holdings Inc....
...tumor response rate, duration of response and antibodies Status: Interim Phase I data Milestone: NA Sandi Wong MVT-1075 MabVax Therapeutics Holdings Inc. CA19.9...
BioCentury | Nov 2, 2017
Product R&D

Sweet specificity

...status for the most advanced is shown. Funding totals do not include public grants. (A) MabVax Therapeutics Holdings Inc....
...GmbH 2001 $134.0 PankoMab-GEX IgG antibody targeting a mucin 1(MUC1; CD227) glycopeptide epitope Phase II MabVax Therapeutics Holdings Inc....
BioCentury | Jul 7, 2017
Finance

Generalists needed

...NASDAQ:HALO) 5/18/17 $143.8 $1,766.8 $1,811.7 3% Repros Therapeutics Inc. (NASDAQ:RPRX) 5/18/17 $3.0 $17.7 $13.6 -23% MabVax Therapeutics Holdings Inc....
BioCentury | Jul 7, 2017
Clinical News

MabVax begins Phase I of MVT-1075 in CA19.9-positive cancers

...is a human IgG1 mAb targeting an epitope on CA19.9 coupled to the radioisotope lutetium-177. MabVax Therapeutics Holdings Inc....
...response and antibodies Status: Phase I started Milestone: Interim Phase I data (year end 2017) Julian Zhu MVT-1075 MabVax Therapeutics Holdings Inc. CA19.9...
BioCentury | Jun 15, 2017
Tools & Techniques

Clearing chemistry

...own barrage of tests. Steve Schow, an industry consultant and former VP of R&D at Telik...
BioCentury | Jun 9, 2017
Clinical News

MabVax reports Phase Ia data for MVT-5873 in pancreatic cancer

...the trial this year. MVT-5873 is a human IgG1 mAb targeting an epitope on CA19.9. MabVax Therapeutics Holdings Inc....
...Status: Phase Ia data Milestone: Additional Phase Ia data (2017) Julian Zhu 5B1 antibody HuMab-5B1 MVT-5873 American Society of Clinical Oncology MabVax Therapeutics Holdings Inc. CA19.9 ASCO...
Items per page:
1 - 10 of 334
BioCentury | Jul 9, 2019
Financial News

BioNTech broadens investor base with $325M B round

...generation unit of MAB Discovery GmbH in January and its purchase of antibody assets from MabVax Therapeutics Holdings Inc....
BioCentury | Jun 28, 2019
Preclinical News

June 28 Preclinical Quick Takes: BioNTech targets pancreatitis; plus new targets for HIV and more

...CSHL filed a patent application on using anti-CA19.9 mAbs to treat and prevent pancreatitis, which MabVax Therapeutics Holdings Inc....
BioCentury | May 8, 2019
Company News

May 8 Company Quick Takes: Takeda selling Shire eye drug to Novartis in $3.4B deal; plus BioNTech, Third Rock’s Thrive and more

...Diego through its acquisition of antibody assets, including MVT-5873, and infrastructure and lab equipment from MabVax Therapeutics Holdings Inc....
...Chris Lieu Xiidra, lifitegrast (SAR 1118, SHP606) Amgen Inc. BioNTech AG Chiesi Farmaceutici S.p.A. Jiangsu Hansoh Pharmaceutical Co. Ltd. Johnson & Johnson MabVax Therapeutics Holdings Inc. Novartis...
BioCentury | Sep 7, 2018
Financial News

Opko's Frost among those charged in ‘pump-and-dump’ schemes

...said are led by Barry Konig. Two of the companies -- Biozone Pharmaceuticals Inc. and MabVax Therapeutics Holdings Inc....
...New York. Biozone Pharmaceuticals Inc. merged with Cocrystal Pharma Inc. (OTCQB:COCP) in 2014. Allison Johnson Biozone Pharmaceuticals Inc. MabVax Therapeutics Holdings Inc. Opko...
BioCentury | Mar 9, 2018
Clinical News

MabVax reports Phase I data for cancer candidate MVT-1075

...is a human IgG1 mAb targeting an epitope on CA19.9 coupled to the radioisotope lutetium-177. MabVax Therapeutics Holdings Inc....
...tumor response rate, duration of response and antibodies Status: Interim Phase I data Milestone: NA Sandi Wong MVT-1075 MabVax Therapeutics Holdings Inc. CA19.9...
BioCentury | Nov 2, 2017
Product R&D

Sweet specificity

...status for the most advanced is shown. Funding totals do not include public grants. (A) MabVax Therapeutics Holdings Inc....
...GmbH 2001 $134.0 PankoMab-GEX IgG antibody targeting a mucin 1(MUC1; CD227) glycopeptide epitope Phase II MabVax Therapeutics Holdings Inc....
BioCentury | Jul 7, 2017
Finance

Generalists needed

...NASDAQ:HALO) 5/18/17 $143.8 $1,766.8 $1,811.7 3% Repros Therapeutics Inc. (NASDAQ:RPRX) 5/18/17 $3.0 $17.7 $13.6 -23% MabVax Therapeutics Holdings Inc....
BioCentury | Jul 7, 2017
Clinical News

MabVax begins Phase I of MVT-1075 in CA19.9-positive cancers

...is a human IgG1 mAb targeting an epitope on CA19.9 coupled to the radioisotope lutetium-177. MabVax Therapeutics Holdings Inc....
...response and antibodies Status: Phase I started Milestone: Interim Phase I data (year end 2017) Julian Zhu MVT-1075 MabVax Therapeutics Holdings Inc. CA19.9...
BioCentury | Jun 15, 2017
Tools & Techniques

Clearing chemistry

...own barrage of tests. Steve Schow, an industry consultant and former VP of R&D at Telik...
BioCentury | Jun 9, 2017
Clinical News

MabVax reports Phase Ia data for MVT-5873 in pancreatic cancer

...the trial this year. MVT-5873 is a human IgG1 mAb targeting an epitope on CA19.9. MabVax Therapeutics Holdings Inc....
...Status: Phase Ia data Milestone: Additional Phase Ia data (2017) Julian Zhu 5B1 antibody HuMab-5B1 MVT-5873 American Society of Clinical Oncology MabVax Therapeutics Holdings Inc. CA19.9 ASCO...
Items per page:
1 - 10 of 334